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In order to improve risk stratification and clinical management of the pancreatic
ductal adenocarcinoma (PDAC), the American Joint Committee on Cancer
(AJCC) has published its eighth edition staging manual. Some major changes
have been introduced in the new staging system for both T and N categories.
Given the rarity of resectable disease, distal pancreatic cancer is likely
underrepresented in the published clinical studies, and how the impact of the
staging system actually reflects on to clinical outcomes remain unclear.
AIM
To validate the AJCC 8th edition of TNM staging in distal PDAC.
METHODS
A retrospective cohort study was performed in seven academic medical centers in
the United States. Clinicopathological prognostic factors associated with
progression-free survival (PFS) and overall survival (OS) were evaluated through
univariate and multivariate analyses.
RESULTS
Overall, 454 patients were enrolled in the study, and were divided into 2
subgroups: Invasive intraductal papillary mucinous neoplasms (IPMN) (115
cases) and non-IPMN associated adenocarcinoma (339 cases). Compared to
invasive IPMN, non-IPMN associated adenocarcinomas are more common in
relatively younger patients, have larger tumor size, are more likely to have
positive lymph nodes, and are associated with a higher tumor (T) stage and nodal
(N) stage, lymphovascular invasion, perineural invasion, tumor recurrence, and a
worse PFS and OS. The cohort was predominantly categorized as stage 3 per
AJCC 7th edition staging manual, and it’s more evenly distributed based on 8th
edition staging manual. T and N staging of both 7th and 8th edition sufficiently
stratify PFS and OS in the entire cohort, although dividing into N1 and N2
according to the 8th edition does not show additional stratification. For PDAC
arising in IPMN, T staging of the 7th edition and N1/N2 staging of the 8th edition
appear to further stratify PFS and OS. For PDAC without an IPMN component, T
staging from both versions fails to stratify PFS and OS.
CONCLUSION
The AJCC 8th edition TNM staging system provides even distribution for the T
staging, however, it does not provide better risk stratification than previous
staging system for distal pancreatic cancer.
Key words: Pancreatic cancer; Pancreatic ductal adenocarcinoma; Prognosis; Intraductal
papillary mucinous neoplasms; Survival; American Joint Committee on Cancer
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Core tip: The American Joint Committee on Cancer 8th edition TNM staging system
provides even distribution for the T staging, however, it does not provide better risk
stratification than previous staging system for distal pancreatic cancer. This study also
demonstrates the significant difference of clinical outcome and risk stratification
between invasive intraductal papillary mucinous neoplasms and non-intraductal papillary
mucinous neoplasms associated pancreatic ductal adenocarcinoma.
Citation: Yin F, Saad M, Xie H, Lin J, Jackson CR, Ren B, Lawson C, Karamchandani DM,
Bernabeu BQ, Jiang W, Dhir T, Zheng R, Schultz CW, Zhang D, Thomas CL, Zhang X, Lai
J, Schild M, Zhang X, Liu X. Validation of American Joint Committee on Cancer 8th edition
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers. In
the United States, PDAC is the fourth leading cause of cancer related deaths causing
approximately 7% of all cancer mortalities, and has a dismal 5-year survival rate of
less than 10%[1,2]. A strong contributor to the low overall survival (OS) rate is a lack of
early diagnostic symptoms, which results in PDAC frequently presenting at a late
stage with locally advanced or metastatic disease[3].
In order to improve risk stratification, staging, and clinical management of PDAC,
the American Joint Committee on Cancer (AJCC) published its eighth edition staging
manual  for  pancreatic  cancer  in  October  2016[4].  Some major  changes  have been
introduced in the new staging system for both T and N categories. Of note, tumor size
has  become  the  only  factor  for  the  T  staging  except  for  pT4.  pT1  is  further
subclassified into T1a (tumor 0.5 cm or less), T1b (tumor greater than 0.5 cm and less
than 1 cm), and T1c (tumor greater than 1 cm but no more than 2 cm). The most
important change was to replace the requirement of extra-pancreatic extension with
tumor  size  (tumor  greater  than  4  cm)  for  a  pT3  tumor.  For  the  N  category,  N1
(regional lymph node metastasis) is subclassified into N1 (metastasis in 1-3 nodes)
and N2 (metastasis in 4 or more nodes) in 8th edition staging system[5]. Given the rarity
of  resectable  disease,  distal  pancreatic  cancer  is  likely  underrepresented  in  the
published clinical studies, and how the impact of the staging system actually reflects
on to clinical outcomes remain unclear.
Intraductal papillary mucinous neoplasm (IPMN) is a pancreatic neoplasm with
different epithelial types and histopathological grades[6,7]  that has the potential to
progress into invasive carcinoma. The invasive IPMN and non-IPMN associated
PDAC are likely derived through different molecular pathways[8,9], and reports have
suggested improved survival of patients with invasive IMPN as compared to patients
with non-IPMN associated PDAC[10,11]. However, whether invasive IPMN and non-
IPMN PDAC share similar prognostic factors still remains unclear. So far, there is no
specific staging system for invasive IPMN. Conventionally, it  is staged using the
AJCC system primarily developed and validated for non-IPMN associated PDAC.
The size of the invasive component in invasive IPMN is subjective due to variability
in sampling and measurement techniques and may not be a reliable parameter for
staging.
Until now, the majority of validation studies for AJCC 8th edition were performed
in patients with solely or predominantly PDAC in the head of pancreas[5,12-16].  The
current study was designed to validate the major T and N staging changes by the
AJCC 8th edition of TNM staging manual in a cohort of patients with resected distal
pancreatic carcinoma, as well as in a sub-cohort of patients with invasive IPMN or
non-IPMN associated PDAC. Univariate and multivariable survival analyses were
performed to identify prognostic factors in a multi-centered large-scale study.
MATERIALS AND METHODS
Patient characteristics
After  approval  from Institutional  Review Boards from individual  institutions,  a
retrospective cohort study was performed with cases collected from seven academic
medical  centers  in  the  United  States  (University  of  Florida,  Indiana  University,
Dartmouth-Hitchcock Medical Center, Penn State Health Hershey Medical Center,
Thomas Jefferson University Hospital, University of Rochester Medical Center, and
Yale University).
Clinicopathological data of resected distal PDAC cases were retrieved from year
2005  to  2018.  Other  tumor  subtypes  such  as  non-invasive  IPMN,  non-invasive
mucinous cystic neoplasm, neuroendocrine neoplasm, and acinar cell carcinoma were
excluded. Those cases which underwent preoperative neoadjuvant therapy were
excluded from this study.
Histopathology review
Histopathological data were collected through reviewing pathology reports and glass
slides.  Oncological  information  was  collected  including  tumor  size,  type,
differentiation, margin status,  splenic vasculature involvement,  and lymph node
status. All cases were re-staged based on the AJCC 7th and 8th edition, respectively.
Splenic vein involvement was defined as tumor invading through the venous wall.
Splenic artery involvement was defined as tumor invading into or through the arterial
wall.
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Clinical information review
Clinical information including patient’s age, gender, radiographic studies, recurrence,
metastasis, and survival status was collected through reviewing the medical records
from the time of resection until September 2018. The progression free survival (PFS) is
defined as the interval between the date of surgery and the date of initial recurrence
and/or metastasis of tumor or death. The OS is defined as the interval between the
date of surgery and the date of death.
Statistical analysis
Continuous variables were summarized as median and interquartile range (IQR) and
compared with Wilcoxon rank sum test. Categorical variables were summarized as
counts and percentages and compared with Fisher’s exact test.  PFS and OS were
evaluated using Kaplan-Meier curves, and analyzed using log-rank analysis. Cox
proportional hazards regression models were used in univariate and multivariable
survival analyses to identify factors associated with PFS and OS. The proportionality
assumption was assessed graphically using log (-log) plots and quantitatively using
the Z statistic. All tests were two-sided and performed in R (version 3.5.3). A P value
of < 0.05 was considered statistically significant.
RESULTS
Patient characteristics
The study enrolled 454 patients with resected distal pancreatic cancer. The age of the
patients ranged from 27 to 91 years,  with a mean age of  67.1 years,  53.5% of the
patients  were  female  (n  =  243),  and  46.5%  were  male  (n  =  211).  Pathologic
demographics and major pathologic features are summarized in Table 1.
Stratification of patient survival in entire cohort
The majority of patients were categorized as stage pT3 per AJCC 7th edition staging
manual, with 32 patients (7.0%), 50 patients (11.0%), and 351 patients (77.3%) being
classified as pT1, pT2, and pT3, respectively. When categorizing based upon the AJCC
8th edition staging manual, the distribution was relatively more even, with 76 patients
(16.7%), 202 patients (44.5%), and 166 patients (36.6%) classified as pT1, pT2, and pT3,
respectively. T staging of both 7th and 8th systems sufficiently stratified PFS and OS in
the entire cohort (Figure 1A, B, E and F).
Among the  237 patients  with positive  lymph nodes  (pN1 per  7th  edition),  180
patients (75.9%) were classified as pN1, and 57 patients (24.1%) were classified as pN2
based on AJCC 8th edition. N staging of both 7th and 8th systems sufficiently stratified
PFS and OS in the entire cohort, although dividing into N1 and N2 according to the 8th
edition did not show additional stratification (Figure 1C, D, G and H).
Invasive IPMN vs non-IPMN-associated adenocarcinoma
The diagnostic  group (IPMN vs  non-IPMN) is  an important  prognostic  factor  in
resected distal pancreatic cancer. In the cohort, 115 patients (25.3%) and 339 patients
(74.7%)  were  diagnosed  as  invasive  IPMN  and  non-IPMN  associated  PDAC,
respectively. There was no gender difference between the 2 groups, with a slight
female predominance in both groups (53.0% female in IPMN group vs 53.7% in non-
IPMN group). Compare to the invasive IPMN group, non-IPMN associated PDAC are
more commonly seen in relatively younger patients (median age 66.7 years in non-
IPMN group vs  70.0 years in IPMN group; P  = 0.003), and have larger tumor size
[median tumor size 3.6 cm (IQR: 2.5-5.2) in non-IPMN group vs median tumor size 3.0
cm (IQR: 2.0-4.5) in IPMN group; P = 0.012]. Non-IPMN associated PDAC are also
associated with higher tumor (T) stage and nodal (N) stage, lymphovascular invasion
(LVI), perineural invasion, tumor recurrence, as well as worse PFS and OS (Table 1).
Prognostic factors and stratification of patient survival with invasive IPMN
A total of 115 patients with invasive IPMN were included in the study. Sixty-one
patients (54.0%) were female and fifty-four (47.0%) were male, with the median age of
70.0 years (Table 1).
In univariable analysis for invasive IPMN, tumor size, poor differentiation, pT3
stage (8th edition staging manual), positive lymph node, pN2 stage (8th edition staging
manual), and pathologic splenic vein invasion were significantly associated with both
poor PFS and poor OS. LVI, splenic artery invasion, and splenic parenchyma invasion
were only associated with PFS. Positive resection margin and perineural invasion
were only associated with OS. In multivariable analysis, only pT3 (8th edition staging
manual) remained as independent prognosticator for OS (Table 2).
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Table 1  Clinical and pathological characteristics of pancreatic ductal adenocarcinoma patients
Feature Level Total cohort
Subcohort
Invasive IPMN Non-IPMN associated PDAC P value
Median (IQR)
Age (in yr) 67.6 (60.0, 74.8) 70.0 (64.1, 75.5) 66.7 (59.4, 74.0) 0.003
Tumor size (in cm) 3.5 (2.5, 5.0) 3.0 (2.0, 4.5) 3.6 (2.5, 5.2) 0.012
Median (95%CI)
PFS (in mo) 21.0 (17.0, 27.0) NR (47.0, NR) 17.0 (13.0, 22.0) < 0.001
OS (in mo) 21.0 (19.0, 24.0) 60.0 (28.0, 69.0) 19.0 (18.0, 22.0) < 0.001
n (%)
Gender (male/female) Female 243 (53.5) 61 (53.0) 182 (53.7) 0.991
Male 211 (46.5) 54 (47.0) 157 (46.3)
Tumor differentiation Well 41 (9.0) 15 (13.4) 26 (7.9) 0.103
Moderate 271 (59.7) 71 (63.4) 200 (61.0)
Poor 128 (28.2) 26 (23.2) 102 (31.1)
AJCC 8th ed staging system T1 76 (16.7) 32 (27.8) 44 (13.0) 0.003
T2 202 (44.5) 46 (40.0) 156 (46.2)
T3 166 (36.6) 36 (31.3) 130 (38.5)
AJCC 8th ed staging system N0 216 (47.6) 69 (60.0) 147 (43.4) 0.004
N1 181 (39.9) 31 (27.0) 150 (44.2)
N2 57 (12.6) 15 (13.0) 42 (12.4)
Lymphovascular invasion Positive 219 (48.2) 44 (38.3) 175 (51.6) 0.011
Negative 219 (48.2) 69 (60.0) 150 (44.2)
Indetermi-
nant
16 (3.5) 2 (1.7) 14 (4.1)
Perineural invasion Positive 366 (80.6) 80 (69.6) 286 (84.4) 0.001
Negative 82 (18.1) 34 (29.6) 48 (14.2)
Indetermi-
nant
6 (1.3) 1 (0.9) 5 (1.5)
Recurrence/metastasis Present 218 (48.0) 43 (37.4) 175 (51.6) 0.015
Absent 236 (52.0) 72 (62.6) 164 (48.4)
Splenic parenchymal invasion Present 25 (5.5) 2 (1.7) 23 (6.9) 0.067
Absent 425 (93.6) 113 (98.3) 312 (93.1)
AJCC: American Joint Committee on Cancer; IPMN: Intraductal papillary mucosal neoplasm; PDAC: Pancreatic ductal adenocarcinoma; PFS: Progression-
free survival; OS: Overall survival; IQR: Interquartile range; NR: Not reached.
Per AJCC 7th edition staging manual, 13 patients (11.3%), 21 patients (18.3%), and 77
patients (67.0%) were classified as pT1,  pT2,  and pT3,  respectively.  Per AJCC 8th
edition,  32  patients  (27.8%),  46  patients  (40.0%),  and  36  patients  (31.3%)  were
classified as pT1, pT2 and pT3, respectively. Among 46 patients with lymph node
metastasis  (pN1 per  AJCC 7th  edition),  31  patients  and 15  patients  were  further
diagnosed with pN1 and pN2 tumor according to AJCC 8th edition. T staging of the 7th
system appeared to further stratify PFS and OS, however N1/N2 staging of the 8th
edition appeared to further stratify PFS and OS (Figure 2).
Stratification of patient survival with non-IPMN associated PADC
A total of 339 patients with non-IPMN associated PDAC were included in the study.
One hundred eighty-two patients (53.7%) were female and one hundred fifty-seven
(46.3%) were male, with the median age of 66.7 years (Table 1).
In univariable analysis for non-IPMN associated PADC, nodal metastasis, pN1
stage (8th edition), and LVI were significantly associated with both PFS and OS. Tumor
size,  pathologic or radiographic evidence of  splenic vein invasion,  and adjuvant
chemotherapy were all significantly associated with OS. In multivariable analysis,
however,  only  pN1  (8th  edition  staging  manual)  remained  as  an  independent
prognosticator  for  both PFS and OS,  while  adjuvant  chemotherapy remained as
independent prognosticator for OS only (Table 3).
Per AJCC 7th edition staging manual, 19 patients (5.6%), 29 patients (8.6%), and 274
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Figure 1
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Figure 1  Kaplan-Meier curves for survival of the resected distal pancreatic cancer. A: PFS stratified according to AJCC 7th edition T staging; B: PFS stratified
according to the AJCC 8th edition T staging; C: PFS stratified according to AJCC 7th edition N staging; D: PFS stratified according to the AJCC 8th edition N staging;
E: OS stratified according to AJCC 7th edition T staging; F: OS stratified according to the AJCC 8th edition T staging; G: OS stratified according to AJCC 7th edition N
staging; H: OS stratified according to the AJCC 8th edition N staging. PFS: Progression-free survival; AJCC: American Joint Committee on Cancer; OS: Overall
survival.
patients (80.8%) were classified as pT1,  pT2,  and pT3,  respectively.  Per AJCC 8th
edition staging manual, 44 patients (13.0%), 149 patients (44.0%), and 130 patients
(38.3%) were classified as pT1, pT2 and pT3, respectively. Among 191 patients with
lymph node metastasis (pN1 per AJCC 7th edition staging manual), 149 patients and
42 patients were further sub classified into pN1 and pN2 tumor according to AJCC 8th
edition. For PDAC without IPMN component, T staging from both staging systems
failed to stratify PFS and OS. N staging of both staging systems could stratify PFS and
OS, although dividing N category into pN1 and pN2 as in the 8th  edition staging
manual did not add further value to this group (Figure 3).
DISCUSSION
In this study, we evaluated the prognostic relevance of the 8th edition AJCC TNM
staging manual in a large United States cohort of distal pancreatic cancer. The new
staging system recognizes tumor size as one of the most important prognostic factors
for tumor staging. In practice, the vast majority of PDAC cases had spread into the
peripancreatic soft tissue and were staged as pT3 even after the introduction of the 5th
edition of the AJCC staging manual in 1997. By removing the diagnostic criteria of
extra pancreatic extension for pT3, patients with PDAC are distributed more evenly
using the new AJCC 8th staging system.
Even with relatively  strict  selection criteria,  wide heterogeneity  of  diagnostic
groups  was  still  inevitable  within  our  study  subjects.  To  simply  this  issue,  we
classified the cases as invasive IPMN and non-IPMN-associated adenocarcinoma.
Consistent with previous reports[10,11], invasive IPMN is associated with lower T stage
and N stage, as well as better survival in our study. The study revealed multiple
independent prognostic factors for patients with distal pancreatic cancer, such as poor
differentiation, tumor size, pT3 stage (8th  edition staging manual), positive lymph
node, pN2 stage (8th edition staging manual), LVI, splenic artery or vein invasion,
positive resection margin,  and splenic parenchymal invasion.  Interestingly,  very
limited overlap was observed among patients with invasive IPMN and non-IPMN
associated PDAC. For invasive IPMN patients, pT3 is the only significant prognostic
factor for OS upon multivariable analysis. On the other hand, lymph node metastasis
(pN1 stage per 8th edition) appears to be the only independent prognosticator for both
PFS and OS in non-IPMN-assoiciated adenocarcinoma. The underlying mechanism
account for these differences as well as their distinct clinical behavior and survival is
not clear, but the molecular pathways underlying tumorigenesis for each entity might
provide clues in the future.
Consistent with a recent study[16], our study demonstrates that the AJCC 7th edition
T staging better stratifies survival in patients with invasive IPMN. Tumor size alone is
not  an  independent  prognostic  factor  based  on  multivariable  analysis[16].  It’s
interesting to identify pT3 (8th edition) as the only significant risk factor for survival in
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HR (95%CI), P value
Gender 1.67 (0.91-3.05), P = 0.10 - 1.33 (0.85-2.08), P = 0.22 -
Age 0.99 (0.96-1.02), P = 0.52 - 1.01 (0.98-1.03), P = 0.54 -
Tumor size 1.18 (1.05-1.32), P = 0.01 - 1.10 (1.00-1.21), P = 0.04 -
Tumor differentiation Well - - - -
Moderate 2.71 (0.82-8.91), P = 0.10 12290265.82 (0.00-Inf), P
= 1.00
1.04 (0.53-2.02), P = 0.92 1.62 (0.34-7.66), P = 0.55
Poor 3.88 (1.06-14.27), P = 0.04 2274054.50 (0.00-Inf), P =
1.00
2.31 (1.10-4.86), P = 0.03 1.78 (0.15-20.67), P = 0.64
Positive lymph node 1.19 (1.05-1.35), P = 0.01 - 1.19 (1.07-1.31), P < 0.01 -
T stage (AJCC 8th
edition staging
manual)
T1 - - - -
T2 2.69 (1.14-6.37), P = 0.02 0.81 (0.07-9.31), P = 0.87 1.65 (0.92-2.97), P = 0.09 0.89 (0.09-8.48), P = 0.92
T3 3.48 (1.42-8.51), P = 0.01 5.29 (0.44-62.97), P = 0.19 2.28 (1.23-4.24), P = 0.01 26.22 (2.13-322.77), P =
0.01
N stage (AJCC 8th
edition staging
manual)
N0 - - - -
N1 2.03 (1.03-4.02), P = 0.04 13.78 (1.15-165.63), P =
0.04
1.58 (0.93-2.67), P = 0.09 1.17 (0.24-5.70), P = 0.85
N2 3.65 (1.60-8.34), P < 0.01 29.12 (0.87-979.78), P =
0.06
2.52 (1.36-4.65), P < 0.01 1.63 (0.10-27.11), P = 0.73
Lymphovascular
invasion
2.12 (1.16-3.90), P = 0.02 0.31 (0.04-2.41), P = 0.26 1.43 (0.90-2.28), P = 0.13 -
Perineural invasion 1.99 (0.98-4.04), P = 0.06 - 2.45 (1.39-4.33), P < 0.01 2.67 (0.54-13.22), P = 0.23
Splenic artery invasion 5.30 (1.41-19.94), P = 0.01 2.44 (0.10-62.16), P = 0.59 1.70 (0.59-4.88), P = 0.32 -
Splenic vein invasion 18.69 (4.57-76.48), P <
0.01
5.28 (0.22-129.25), P =
0.31
2.66 (1.08-6.55), P = 0.03 5.62 (0.61-51.99), P = 0.13
Positive margin 1.25 (0.30-5.19), P = 0.76 - 3.14 (1.49-6.62), P < 0.01 0.00 (0.00-Inf), P = 1.00
Splenic parenchyma
invasion
14.93 (1.83-121.81), P =
0.01
1.00 (1.00-1.00), P = NaN 1.23 (0.17-8.87), P = 0.84 -
Adjuvant radiation
therapy
0.97 (0.52-1.81), P = 0.92 - 0.81 (0.48-1.37), P = 0.43 -
Adjuvant
chemotherapy
2.50 (0.89-7.00), P = 0.08 - 0.69 (0.39-1.22), P = 0.20 -
Radiographic splenic
artery invasion
2.12 (0.85-5.29), P = 0.11 - 1.45 (0.59-3.56), P = 0.41 -
Radiographic splenic
vein invasion
2.27 (1.04-4.94), P = 0.04 2.88 (0.33-24.96), P = 0.34 1.46 (0.68-3.13), P = 0.33 -
AJCC: American Joint Committee on Cancer; PFS: Progression-free survival; OS: overall survival.
our study. One possible explanation is that majority of the pT3 tumor (> 4 cm per 8th
edition staging manual) extend into peripancreatic soft tissue, and would also be
staged as pT3 per the 7th edition staging manual[17]. In contrast to the T staging, N1/N2
staging of the 8th edition staging manual appears to further stratify PFS and OS in
invasive IPMN.
An unexpected finding in this study is that T staging from both staging systems
failed to stratify PFS and OS in resected distal non-IPMN associated PDAC. Multiple
studies  have  demonstrated  the  clinical  relevance,  reproducibility,  and  risk
stratification of the AJCC 8th edition staging manual[5,12-15]. However, due to the relative
rarity,  resected  distal  PDAC is  likely  underrepresented  among those  published
studies. It should be noted that the stage-independent OS in distal pancreatic cancer is
much worse as compared to its counterpart in the pancreatic head, and tumor location
itself has been considered as a prognostic factor for survival in pancreatic cancer
patients[18,19].  Delay in diagnosis is  likely the major reason for its  poor prognosis,
although other  facts  may also  play a  role.  For  example,  distal  pancreatic  cancer
patients are significantly older at the time of diagnosis, and less dissectible lymph
nodes are present at  the distal  portion of the pancreas[19].  Unlike invasive IPMN,
lymph node metastasis is the most important prognostic factor for survival in non-
IPMN associated PDAC. N staging of both 7th and 8th edition could stratify PFS and
WJGPT https://www.wjgnet.com June 9, 2020 Volume 11 Issue 2
Yin F et al. Validation of TNM staging in distal pancreatic cancer
32
Figure 2
WJGPT https://www.wjgnet.com June 9, 2020 Volume 11 Issue 2
Yin F et al. Validation of TNM staging in distal pancreatic cancer
33
Figure 2  Kaplan-Meier curves for survival of the invasive intraductal papillary mucinous neoplasm. A: PFS stratified according to AJCC 7th edition T staging;
B: PFS stratified according to the AJCC 8th edition T staging; C: PFS stratified according to AJCC 7th edition N staging; D: PFS stratified according to the AJCC 8th
edition N staging; E: OS stratified according to AJCC 7th edition T staging; F: OS stratified according to the AJCC 8th edition T staging; G: OS stratified according to
AJCC 7th edition N staging; H: OS stratified according to the AJCC 8th edition N staging. PFS: Progression-free survival; AJCC: American Joint Committee on Cancer;
OS: Overall survival.
OS, although dividing N category into pN1 and pN2 in the 8th edition staging manual
did  not  add  further  value  in  this  group.  The  prognostic  value  of  lymph  node
involvement has also been reported in a recent large scaled multi-institutional study.
Morales-Oyarvide et al[20] demonstrated that the AJCC 8th edition staging system was a
practical classification of lymph node involvement. Similar to other related validation
studies[5,12-16], predominant patient population in this study (74%) had PDAC in the
head of pancreas, and only 14% of the patients had PDAC in the tail of pancreas.
Notably, the prognostic value of lymph node involvement was weaker in patients
with resected distal pancreatic cancer[20].
This study has several strengths. It was a multicentered large-scale study designed
to validate the major changes in the newer AJCC TNM staging system for resected
distal pancreatic cancers. This study provides important insights for future revision of
the AJCC staging system. Furthermore, all cases were re-staged according to the AJCC
7th or 8th edition and re-reviewed by pathologists subspecialized in gastrointestinal
and pancreatic pathology. In addition, we included several potentially prognostic
parameters  such  as  radiographic  evidence  and  histologic  evidence  of  splenic
vasculature and parenchymal invasion. In our study, we also compared the clinical
behavior and risk stratification for invasive IPMN and non-IPMN associated PDAC.
Our study also has some limitations. First,  all  cases were collected from major
academic cancer centers that might have introduced selection bias. Second, the cases
were collected from a 13-year period of  time (2005-2018)  during which multiple
different AJCC staging editions (5th to 7th edition) had been applied for pancreatic
cancer staging. However, all cases in this study were re-staged according to the 7th
and 8th  AJCC editions. The size of invasive IPMN was recorded from the surgical
pathology  report  as  this  parameter  is  difficult  to  generate  as  it  depends  on  the
combination of macroscopic examination, sampling, and histology; histology review
with measurement on slide alone does not provide an accurate assessment of this
parameter.
In conclusion,  our study demonstrates  that  the AJCC 8th  edition TNM staging
system provides even distribution for the T staging, however, it does not improve risk
stratification  when  compared  to  previous  staging  system  for  resectable  distal
pancreatic cancers. Our study also demonstrates the significant difference of clinical
outcome and risk stratification between invasive IPMN and non-IPMN associated
PDAC. Our study indicates that tumor location and subtype are important factors to
be considered in future revisions of the AJCC staging system for pancreatic cancer.
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Table 3  Univariate and multivariable analysis for progression-free survival and overall survival in non-intraductal papillary mucinous
neoplasm pancreatic ductal adenocarcinoma
Feature Level
PFS OS
HR (95%CI), P value
Gender 0.89 (0.66-1.20), P = 0.43 - 1.05 (0.82-1.35), P = 0.69 -
Age 0.99 (0.98-1.01), P = 0.29 - 1.01 (1.00-1.03), P = 0.05 1.00 (0.98-1.02), P = 0.93
Tumor size 1.07 (0.99-1.15), P = 0.09 - 1.08 (1.02-1.16), P = 0.01 -
Tumor differentiation Well - - - -
Moderate 1.11 (0.64-1.91), P = 0.71 - 1.33 (0.78-2.27), P = 0.29 1.56 (0.65-3.78), P = 0.32
Poor 1.21 (0.68-2.14), P = 0.52 - 1.72 (0.99-2.98), P = 0.05 2.23 (0.90-5.53), P = 0.08
Positive lymph node 1.06 (1.01-1.12), P = 0.03 - 1.08 (1.03-1.13), P < 0.01 -
T stage (AJCC 8th
edition staging
manual)
T1 - - - -
T2 1.39 (0.83-2.31), P = 0.21 1.22 (0.73-2.05), P = 0.45 0.97 (0.64-1.46), P = 0.87 1.12 (0.57-2.20), P = 0.73
T3 1.56 (0.92-2.62), P = 0.10 1.19 (0.68-2.07), P = 0.54 1.33 (0.88-2.03), P = 0.18 0.80 (0.39-1.64), P = 0.54
N stage (AJCC 8th
edition staging
manual)
N0 - - - -
N1 1.73 (1.25-2.39), P < 0.01 1.59 (1.09-2.32), P = 0.02 1.75 (1.33-2.32), P < 0.01 2.54 (1.41-4.58), P < 0.01
N2 1.57 (0.96-2.56), P = 0.07 1.47 (0.82-2.63), P = 0.20 1.83 (1.23-2.72), P < 0.01 2.45 (0.92-6.51), P = 0.07
Lymphovascular
invasion
1.43 (1.05-1.95), P = 0.02 1.07 (0.73-1.56), P = 0.74 1.46 (1.12-1.89), P < 0.01 0.82 (0.45-1.49), P = 0.51
Perineural invasion 1.16 (0.76-1.78), P = 0.48 - 1.19 (0.83-1.73), P = 0.35 -
Splenic artery invasion 1.41 (0.71-2.80), P = 0.33 - 1.38 (0.81-2.36), P = 0.24 -
Splenic vein invasion 1.35 (0.82-2.23), P = 0.24 - 2.09 (1.44-3.03), P < 0.01 1.59 (0.83-3.02), P = 0.16
Positive margin 0.78 (0.43-1.40), P = 0.40 - 1.20 (0.78-1.82), P = 0.41 -
Splenic invasion 1.65 (0.95-2.85), P = 0.07 - 1.32 (0.82-2.11), P = 0.25 -
Adjuvant radiation
therapy
0.93 (0.69-1.27), P = 0.66 - 0.85 (0.64-1.12), P = 0.25 -
Adjuvant
chemotherapy
1.45 (0.90-2.34), P = 0.13 - 0.51 (0.37-0.71), P < 0.01 0.34 (0.20-0.58), P < 0.01
Radiographic splenic
artery invasion
1.27 (0.87-1.84), P = 0.21 - 1.13 (0.81-1.59), P = 0.47 -
Radiographic splenic
vein invasion
1.26 (0.88-1.80), P = 0.20 - 1.51 (1.10-2.07), P = 0.01 1.08 (0.65-1.80), P = 0.75
AJCC: American Joint Committee on Cancer; PFS: Progression-free survival; OS: Overall survival.
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Figure 3  Kaplan-Meier curves for survival of the non-intraductal papillary mucinous neoplasm associated pancreatic ductal adenocarcinoma. A: PFS
stratified according to AJCC 7th edition T staging; B: PFS stratified according to the AJCC 8th edition T staging; C: PFS stratified according to AJCC 7th edition N
staging; D: PFS stratified according to the AJCC 8th edition N staging; E: OS stratified according to AJCC 7th edition T staging; F: OS stratified according to the AJCC
8th edition T staging; G: OS stratified according to AJCC 7th edition N staging; H: OS stratified according to the AJCC 8th edition N staging. PFS: Progression-free
survival; AJCC: American Joint Committee on Cancer; OS: Overall survival.
ARTICLE HIGHLIGHTS
Research background
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer related death
worldwide. For the purpose of better risk stratification and clinical management, the American
Joint Committee on Cancer (AJCC) published the eighth edition staging manual for pancreatic
cancer that has introduced significant changes for both tumor (T) staging and nodal (N) staging.
Notably majority of the validation studies were focused on PDAC in the head of pancreas, and
the resected distal pancreatic adenocarcinoma was likely underrepresented due to its clinical
rarity. Whether the AJCC 8th edition staging manual provides equal risk stratification for both
invasive intraductal papillary mucinous neoplasm (IPMN) and non-IPMN associated PDAC is
also unclear.
Research motivation
It’s important to investigate whether the new AJCC staging system provides risk stratification in
patients with distal pancreatic cancers. It’s also important to investigate the clinical behavior and
risk stratification for invasive IPMN and non-IPMN associated PDAC.
Research objectives
This study aims to validate the AJCC 8th edition staging manual in distal PDAC.
Research methods
Clinicopathological data of resected distal PDAC cases were retrieved. All cases were re-staged
based on the AJCC 7th and 8th edition, respectively. Categorical variables were compared with
Fisher’s exact test. Progression-free survival (PFS) and overall survival (OS) were evaluated
through Kaplan-Meier curves and univariate/multivariate analyses.
Research results
T and N staging of both 7th and 8th edition sufficiently stratify PFS and OS in the entire cohort,
although  dividing  into  N1  and  N2  according  to  the  8th  edition  does  not  show  additional
stratification. For PDAC arising in IPMN, T staging of the 7th edition and N1/N2 staging of the
8th edition appear to further stratify PFS and OS. For PDAC without an IPMN component, T
staging from both versions fails to stratify PFS and OS.
Research conclusions
The AJCC 8th edition TNM staging system provides even distribution for the T staging, however,
it does not provide better risk stratification than previous staging system for distal pancreatic
cancer. There is significant difference of clinical outcome and risk stratification between invasive
IPMN and non-IPMN associated PDAC.
Research perspectives
Tumor location and subtype are important factors to be considered in future revisions of the
AJCC staging system for pancreatic cancer.
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